Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Saturday morning. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

Shares of NYSE:OGEN opened at $0.35 on Friday. Oragenics has a 1 year low of $0.29 and a 1 year high of $7.74. The company has a market cap of $1.55 million, a P/E ratio of -0.04 and a beta of 0.45. The stock’s fifty day moving average price is $0.68 and its 200-day moving average price is $1.14.

Oragenics (NYSE:OGEN) last issued its earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Investors Weigh In On Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new position in Oragenics, Inc. (NYSE:OGEN) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics at the end of the most recent reporting period. 18.71% of the stock is owned by hedge funds and other institutional investors.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.